Trials / Suspended
SuspendedNCT06855628
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | [6,6-²H₂]-Glucose | \[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI). |
Timeline
- Start date
- 2025-01-30
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2025-03-04
- Last updated
- 2025-10-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06855628. Inclusion in this directory is not an endorsement.